These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 29241903

  • 1. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
    Guo WQ, Li L, Su Q, Dai WR, Ye ZL.
    Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
    [Abstract] [Full Text] [Related]

  • 2. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J, Huang C, Wu S, Xu Y, Cai T, Chai S, Yang Z, Sun F, Zhan S.
    PLoS One; 2017 Dec; 12(12):e0187537. PubMed ID: 29206832
    [Abstract] [Full Text] [Related]

  • 3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ.
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [Abstract] [Full Text] [Related]

  • 4. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 5. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

  • 6. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M, Narukawa M.
    Ann Pharmacother; 2017 Jul 01; 51(7):570-576. PubMed ID: 28622738
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Wu S, Chai S, Yang J, Cai T, Xu Y, Yang Z, Zhang Y, Ji L, Sun F, Zhan S.
    Clin Ther; 2017 Sep 01; 39(9):1780-1789.e33. PubMed ID: 28827024
    [Abstract] [Full Text] [Related]

  • 8. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK, Ye C, Campbell S, Retnakaran R.
    JACC Heart Fail; 2018 Oct 01; 6(10):823-830. PubMed ID: 30196071
    [Abstract] [Full Text] [Related]

  • 9. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM.
    Int J Cardiol; 2016 Oct 01; 220():14-20. PubMed ID: 27389437
    [Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F.
    Nutr Metab Cardiovasc Dis; 2016 May 01; 26(5):380-6. PubMed ID: 27067162
    [Abstract] [Full Text] [Related]

  • 11. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials.
    Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N.
    Int J Cardiol; 2016 May 15; 211():88-95. PubMed ID: 26991555
    [Abstract] [Full Text] [Related]

  • 12. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
    Monami M, Dicembrini I, Mannucci E.
    Nutr Metab Cardiovasc Dis; 2014 Jul 15; 24(7):689-97. PubMed ID: 24793580
    [Abstract] [Full Text] [Related]

  • 13. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr 15; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
    Mannucci E, Nreu B, Montereggi C, Ragghianti B, Gallo M, Giaccari A, Monami M, SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes.
    Nutr Metab Cardiovasc Dis; 2021 Sep 22; 31(10):2745-2755. PubMed ID: 34364771
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May 22; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

  • 16. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
    Scheen AJ.
    Expert Opin Drug Saf; 2015 Apr 22; 14(4):505-24. PubMed ID: 25630605
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
    Ryan G.
    Postgrad Med; 2015 Apr 22; 127(8):842-54. PubMed ID: 26436470
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 22; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.